Evolus, Inc. (NASDAQ:EOLS) Insider Sells $24,434.20 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 2,252 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.85, for a total value of $24,434.20. Following the completion of the sale, the insider now directly owns 366,595 shares of the company’s stock, valued at approximately $3,977,555.75. The trade was a 0.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Evolus Trading Down 2.3 %

Shares of EOLS stock opened at $11.09 on Friday. Evolus, Inc. has a 12 month low of $9.80 and a 12 month high of $17.82. The company has a market cap of $702.23 million, a PE ratio of -12.19 and a beta of 1.27. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The business’s 50 day moving average is $13.35 and its two-hundred day moving average is $13.73.

Analyst Upgrades and Downgrades

EOLS has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research note on Friday, September 13th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, November 7th. Finally, Barclays raised their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th.

Institutional Trading of Evolus

Several large investors have recently modified their holdings of EOLS. Quest Partners LLC acquired a new position in Evolus during the 2nd quarter worth $43,000. Quarry LP bought a new position in shares of Evolus in the second quarter worth about $54,000. Profund Advisors LLC acquired a new position in shares of Evolus during the 2nd quarter worth about $130,000. Point72 Asset Management L.P. bought a new stake in Evolus during the 3rd quarter valued at approximately $132,000. Finally, Arizona State Retirement System boosted its stake in Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after purchasing an additional 1,253 shares during the period. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.